Search

Genmab A-S

Uždarymo kaina

2,153 0.65

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2125

Max

2170

Pagrindiniai rodikliai

By Trading Economics

Pajamos

243M

295M

Pardavimai

259M

1.2B

P/E

Sektoriaus vid.

25.63

57.371

Pelnas, tenkantis vienai akcijai

34.85

Pelno marža

25.541

Darbuotojai

3,119

EBITDA

216M

431M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.49% downside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

18B

131B

Ankstesnė atidarymo kaina

2152.35

Ankstesnė uždarymo kaina

2153

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-20 23:56; UTC

Chubb Ltd shares are modestly higher in after-market trading. No specific company news was identified to explain this movement.

2026-08-20 23:56; UTC

Centene Corp. shares are higher in after-market hours, recovering slightly following three consecutive lower sessions. No specific news has been identified.

2026-08-20 23:56; UTC

Correlated Moves

Hancock Whitney Corp shares were little changed after hours, following a session where the Russell 2000 Index gained slightly. The stock has declined for six straight sessions.

2026-08-20 23:56; UTC

Lexicon Pharmaceuticals Inc shares are rising in after-market trading, showing positive momentum despite being below their 20-day moving average. No specific news was identified.

2026-08-20 23:56; UTC

Astronics Corp shares are higher in after-market hours, diverging from a broader market decline amid rising Treasury yields and geopolitical tensions.

2026-08-20 23:56; UTC

Union Pacific Corp shares are higher in after-market trading, reflecting a recovery from earlier lows amid rising U.S. Treasury yields and oil prices.

2026-08-20 23:56; UTC

Correlated Moves
ETF Constituents

iShares MSCI Canada ETF trades lower in after-market hours, impacted by negative returns from key holdings CNQ and KGC, despite positive USD/CAD movement.

2026-08-20 23:56; UTC

Energy Recovery Inc's shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026-08-20 23:56; UTC

Correlated Moves
News

The Vanguard Mortgage-Backed Securities ETF remains roughly flat in after-market trading amid rising yields and concerns over high borrowing costs and geopolitical risks.

2026-08-20 23:56; UTC

Old National Bancorp shares are lower in after-market hours following a volatile session, amid rising U.S. Treasury yields and geopolitical tensions.

2026-08-20 23:56; UTC

LyondellBasell Industries NV shares are trading higher in after-market hours. The move comes amid rising U.S. Treasury yields and geopolitical tensions.

2026-08-20 23:56; UTC

Antero Resources Corp. experienced routine trading activity after market hours, remaining roughly flat. The stock is positioned above its 20-day moving average.

2026-08-20 23:56; UTC

Correlated Moves

Synchrony Financial shares are higher in after-market trading, though they remain below their 20-day moving average after five consecutive lower daily closes.

2026-08-20 23:56; UTC

Amplitude Inc shares are higher in after-market hours, though no specific news was identified. The stock has performed well since July 21.

2026-08-20 23:56; UTC

Yeti Holdings Inc. shares traded roughly flat in after-market hours, remaining near the lower end of their one-month range amid a weaker performance backdrop.

2026-08-20 23:56; UTC

DTE Energy Co. shares are lower in after-market trading, continuing a decline amid rising U.S. Treasury yields and increasing oil prices.

2026-08-20 23:56; UTC

CoStar Group Inc shares are higher in after-market trading, remaining above their 20-day moving average despite no specific news identified.

2026-08-20 23:56; UTC

Comstock Resources Inc. shares are trading higher in after-market hours, amid rising U.S. Treasury yields and increasing oil prices. No specific news was identified.

2026-08-20 23:56; UTC

Immunovant Inc shares are lower in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026-08-20 23:56; UTC

Aptiv PLC shares are trading higher in after-market hours, recovering from an initial dip. No specific news was identified to explain the movement.

2026-08-20 23:56; UTC

Enovix Corp shares were roughly flat in after-market hours. The asset remains significantly lower compared to its performance over the past month.

2026-08-20 23:56; UTC

American Express shares are trading higher in after-market hours, despite remaining below their 20-day moving average and near the lower end of their one-month range.

2026-08-20 23:56; UTC

Allstate Corp shares traded roughly flat in after-market hours amid rising U.S. Treasury yields and ongoing geopolitical tensions related to U.S.-Iran relations.

2026-08-20 23:56; UTC

Correlated Moves
Macro News
ETF Constituents

KOSPI rises significantly, bolstered by financial shares, while after-market trading shows gains for the Financial Select Sector SPDR Fund amid rising crude oil prices.

2026-08-20 23:56; UTC

United States Oil Fund LP is trading lower in after-market hours, continuing a decline since Thursday's close amid mixed global equity performance.

2026-08-20 23:56; UTC

Correlated Moves
Macro News
ETF Constituents

The iShares MSCI Japan ETF is higher in after-market trading, reflecting a rebound in the Japanese stock market despite negative USD/JPY impacts.

2026-08-20 23:56; UTC

Social Media

Alibaba Group Holding Ltd shares are lower in after-market trading, currently at $130.29, facing resistance at $132 amid a recent decline in market sentiment.

2026-08-20 23:56; UTC

ETF Constituents

OSIS led declines among Vanguard Information Technology ETF holdings, while the ETF traded little changed in after-market hours following mixed global equity performance.

2026-08-20 23:56; UTC

Horace Mann Educators Corp shares are lower in after-market trading, continuing a decline since Thursday's close amid rising Treasury yields and geopolitical tensions.

2026-08-20 23:56; UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK  -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

3

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat